Spontaneous bacterial peritonitis secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 13: Line 13:
!Duration of treatment  
!Duration of treatment  
|-  
|-  
|
|valign=top|
* Norfloxacin 400 mg PO daily
* Norfloxacin 400 mg PO daily
|
|
Line 20: Line 20:
* Levofloxacin 250 mg PO daily.   
* Levofloxacin 250 mg PO daily.   
* Rifaximin
* Rifaximin
|
|valign=top|
* Indefinite, unless ascites resolves.
* Indefinite, unless ascites resolves.
|}  
|}  

Revision as of 23:45, 28 January 2017

Peritonitis main page

Spontaneous bacterial peritonitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Spontaneous bacterial peritonitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Spontaneous bacterial peritonitis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Spontaneous bacterial peritonitis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Spontaneous bacterial peritonitis secondary prevention

CDC on Spontaneous bacterial peritonitis secondary prevention

Spontaneous bacterial peritonitis secondary prevention in the news

Blogs on Spontaneous bacterial peritonitis secondary prevention

Directions to Hospitals Treating Spontaneous bacterial peritonitis

Risk calculators and risk factors for Spontaneous bacterial peritonitis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2] Shivani Chaparala M.B.B.S [3]

Overview

Following a first episode of spontaneous bacterial peritonitis, the recurrence rate at one year is ~70%, with a 1-year overall survival rate of 30-50% in patients who do not receive antibiotic prophylaxis.Cirrhotic patients with ascites with a prior history of SBP, on receiving antibiotic prophylaxis there is a reduction in the risk of recurrence from 68% to 20%.Accordingly, most experts recommend daily long-term antimicrobial prophylaxis for patients with a history of one or more episodes of SBP.

Secondary Prevention

  • Secondary SBP prophylaxis
Preferred therapy Alternative therapy Duration of treatment
  • Norfloxacin 400 mg PO daily
  • Trimethoprim-sulfamethoxazole one DS tablet daily.
  • Ciprofloxacin 500 mg PO daily.
  • Levofloxacin 250 mg PO daily.
  • Rifaximin
  • Indefinite, unless ascites resolves.

Several studies have shown that oral norfloxacin 400 mg daily prevents spontaneous bacterial peritonitis in patients with low-protein ascites and those with previous history of spontaneous bacterial peritonitis (SBP).

  • All patients who have survived an episode of SBP should receive long-term prophylaxis with daily norfloxacin (or trimethoprim/sulfamethoxazole) because this is the most data-supported indication for long-term outpatient prophylaxis to prevent future episodes ( 40-70% risk of recurrence in 1 year ). [1][2]

[3][4]

  • Rifaximin was more effective than norfloxacin in the secondary prevention of SBP as encephalopathy-related mortality and side effects were fewer with rifaximin than norfloxacin.[5][6]

References

  1. http://guideline.gov/content.aspx?id=14887&search=ascitis
  2. Ginés, Pere; Rimola, Antoni; Planas, Ramón; Vargas, Victor; Marco, Francesc; Almela, Manuel; Forne, Montserrat; Miranda, Maria Luisa; Llach, Josep; Salmerón, Joan Manuel; Esteve, Maria; Marques, Josep Maria; de Anta, Maria Teresa Jiménez; Arroyo, Vicente; Rodés, Joan (1990). "Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial". Hepatology. 12 (4): 716–724. doi:10.1002/hep.1840120416. ISSN 0270-9139.
  3. Runyon BA (1986). "Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis". Gastroenterology. 91 (6): 1343–6. PMID 3770358.
  4. Grangé JD, Roulot D, Pelletier G; et al. (1998). "Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial". J. Hepatol. 29 (3): 430–6. PMID 9764990.
  5. Elfert, Asem; Abo Ali, Lobna; Soliman, Samah; Ibrahim, Shimaa; Abd-Elsalam, Sherief (2016). "Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis". European Journal of Gastroenterology & Hepatology. 28 (12): 1450–1454. doi:10.1097/MEG.0000000000000724. ISSN 0954-691X.
  6. Dong, Tien; Aronsohn, Andrew; Gautham Reddy, K.; Te, Helen S. (2016). "Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis". Digestive Diseases and Sciences. 61 (12): 3621–3626. doi:10.1007/s10620-016-4313-0. ISSN 0163-2116.


Template:WikiDoc Sources